Pyc Therapeutics Limited · ASX:PYC
Pyc Therapeutics — Phylogica — Investor Presentation (November 2018)
11 slides from Pyc Therapeutics's investor presentation, Nov 23, 2018
Slide 1: Phylogica FNA Presentation November 2018
For personal use only Phylogica FNA Presentation November 2018 1
Slide 2: Delivery is key
Delivery is key For personal use only • The problem: Delivery to target tissues is the primary obstacle impeding the clinical translation of OligoNucleotide (ON) therapeutics • The solution? Cell Penetrating Peptides (CPPs) are increasingly prominent in the quest to address this delivery obstacle •
Slide 3: A tale of two companies…
A tale of two companies… For personal use only Company Parental CPP CPP sequences Development stage sequences evaluated in lead selection • 1 clinical PPMO 1* 4 • 5 IND submissions for PPMOs planned in 2019 Pre-clinical – 1,000 – 10,000 ~100 therapeutic in vivo validation We are balancing the need t
Slide 4: Phylogica's CPPs are more efficient than 'conventional CPPs'
Phylogica’s CPPs are more efficient than ‘conventional CPPs’ For personal use only 4
Slide 5: Our '1st generation' CPPs are effective in vivo - '2nd gen' results will follow soon
Our ‘1st generation’ CPPs are effective in vivo - ‘2nd gen’ results will follow soon For personal use only Collaborator: Sue Fletcher 5
Slide 6: Indications of cell-specific CPPs suggest further concentration of cargo is possible
Indications of cell-specific CPPs suggest further concentration of cargo is possible For personal use only 6
Slide 7: Recent developments in analytics allow us to consider many more variables
Recent developments in analytics allow us to consider many more variables For personal use only Phylogica’s ‘up-stream’ CPP identification process Peptide source Screening Validation Biophysical Optimisation method method property filter approaches In vitro generic Reporter cargo In vitro specific S
Slide 8: Is the juice worth the squeeze?
Is the juice worth the squeeze? For personal use only • The richness of the data set that we generate from the Phylomer libraries is both a blessing and a curse: • A blessing in the number and quality of CPPs that we identify (Phylogica’s CPPs substantially outperform the ‘conventional CPP landscape
Slide 9: In summary…
In summary… For personal use only • CPPs have the ability to open up new target tissues/cells and disease indications for ON therapeutics • Phylogica’s platform can deliver a step change in the amount of drug delivered into a target cell by: • Using substantially more efficient ‘second generation’ p
Slide 10: Thank you
For personal use only Thank you For more information contact Dr. Rohan Hockings rohanhockings@phylogica.com 10
Slide 11: Disclaimer
Disclaimer For personal use only The purpose of the presentation is to provide an update on the business of Phylogica Limited (ASX:PYC) [‘Phylogica’]. These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Acc